Kalfeist Laura相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Co-targeting TGF-Î² and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet.

共同靶向 TGF-β 和 PD-L1 可使三阴性乳腺癌对实验性免疫原性顺铂-艾立布林双药化疗敏感

期刊:Journal of Clinical Investigation

影响因子:13.6

doi:10.1172/JCI184422

Kalfeist Laura, Ledys Fanny, Petit Stacy, Poirrier Cyriane, Kada Mohammed Samia, Galland LoÃ¯ck, DerangÃ¨re Valentin, Ilie Alis, Rageot David, Aucagne Romain, Bellaye Pierre-Simon, Truntzer Caroline, Thibaudin Marion, Rialland MickaÃ«l, Ghiringhelli FranÃ§ois, Limagne Emeric, Ladoire Sylvain

免疫/内分泌

发表日期：2025

文献求助收藏

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness

通过化疗和靶向治疗调节免疫抑制性肿瘤微环境，以增强免疫疗法的疗效

期刊:Oncoimmunology

影响因子:6.3

doi:10.1080/2162402X.2022.2120676

Barnestein, Robby; Galland, Loïck; Kalfeist, Laura; Ghiringhelli, François; Ladoire, Sylvain; Limagne, Emeric

肿瘤微环境

免疫/内分泌

发表日期：2022

文献求助收藏

Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era

免疫疗法时代糖皮质激素在肿瘤治疗中的影响

影响因子:5.2

doi:10.3390/cells11050770

Kalfeist, Laura; Galland, Loïck; Ledys, Fanny; Ghiringhelli, François; Limagne, Emeric; Ladoire, Sylvain

免疫/内分泌

发表日期：2022

文献求助收藏

Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives

乳腺癌中抗PD-1/PD-L1联合治疗：临床挑战与展望

影响因子:4.4

doi:10.3390/cancers13235999

Ledys, Fanny; Kalfeist, Laura; Galland, Loick; Limagne, Emeric; Ladoire, Sylvain

发表日期：2021

文献求助收藏